In Treatment of Bacterial infections of urinary tract Urifast 50mg Tablet DT works by stopping the growth of the bacteria in the urine that cause urinary tract infections. This medicine usually makes you feel better quite quickly. However, you should continue taking it as long as it is prescribed even when you feel better, to make sure that all bacteria are killed and do not become resistant.
Consuming alcohol while taking Urifast 50mg Tablet DT may cause symptoms such as flushing, increased heart beat, nausea, thirst, chest pain and low blood pressure (Disulfiram reaction).
Urifast 50mg Tablet DT is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.
Urifast 50mg Tablet DT should be used with caution during breastfeeding. Breastfeeding should be held until the treatment of the mother is completed and the drug is eliminated from her body.
Urifast 50mg Tablet DT may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Urifast 50mg Tablet DT should be used with caution in patients with kidney disease. Dose adjustment of Urifast 50mg Tablet DT may be needed. Please consult your doctor. Use of Urifast 50mg Tablet DT is not recommended in patients with severe kidney disease, who are unable to pass urine or have high creatinine levels.
Urifast 50mg Tablet DT should be used with caution in patients with liver disease. Dose adjustment of Urifast 50mg Tablet DT may be needed. Please consult your doctor. Use of Urifast 50mg Tablet DT is not recommended in patients with severe liver disease and active liver disease.
If you miss a dose of Urifast 50mg Tablet DT, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Intas Pharmaceuticals Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Ipca Laboratories Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Lividus Pharmaceuticals Pvt Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Walter Bushnell || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Glaxo SmithKline Pharmaceuticals Ltd || ₹14.5/tablet (25% cheaper)